Pomerantz Law Firm Launches Investigation for Capricor Therapeutics Investors Amid Stock Value Decline

Investor Alert: Pomerantz Law Firm Investigates Capricor Therapeutics

In recent news, the Pomerantz Law Firm has initiated an investigation into claims on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation comes in light of alarming developments regarding Capricor's company practices and substantial dips in their stock value.

Context of the Investigation

On May 5, 2025, Capricor announced that it had completed a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) concerning their Biologics License Application (BLA) for deramiocel. This investigational cell therapy aims to treat patients suffering from Duchenne muscular dystrophy (DMD) cardiomyopathy. Following this announcement, the stock experienced a significant drop of $3.00 per share, equating to a 29.13% fall, closing at $7.30 the following day.

A further twist in the saga occurred on June 20, 2025, when the publication STAT reported that the newly appointed head of the relevant FDA unit had canceled an advisory committee meeting that was crucial for deramiocel's approval. The reason cited was uncertainty regarding the drug's safety and efficacy. Capricor’s stock plunged again, this time by $3.68 per share, or 30.82%, resulting in a close of $8.26.

The situation escalated on July 11, 2025, when Capricor disclosed that it had received a Complete Response Letter (CRL) from the FDA concerning its BLA for deramiocel. This letter indicated that while the FDA had completed its review, it found the application lacking the substantial evidence required for effective approval, citing the need for additional clinical data. The immediate aftermath was a stock price decline of $3.76, approximately 32.98%, closing at $7.64.

The Role of Pomerantz LLP

The Pomerantz Firm, celebrated for its prowess in corporate litigation, particularly in securities cases, is known for advocating on behalf of those victimized by corporate fraud and misconduct. With over eight decades of experience, the firm continues the legacy of its founder, Abraham L. Pomerantz, often referred to as the dean of the class action bar. The firm has successfully recovered substantial damages for countless class members in the past, making their involvement in this situation particularly notable.

Potential investors are urged to stay informed, as updates surrounding this investigation could impact stock movements and the overall future of Capricor Therapeutics. Those affected by these developments and wishing to explore their rights may contact Danielle Peyton at Pomerantz LLP.

As investors closely monitor these proceedings, they should consider the implications of the FDA's communications and the subsequent responses from Capricor. This scenario emphasizes the importance of transparency and ethical practices in biotech firms, where patient outcomes and stakeholder interests intertwine critically.

For more information about this investigation and to join the class action lawsuit, potential participants can reach out via the provided contact details. The Pomerantz Firm is dedicated to ensuring justice for those affected by corporate misconduct.